Loading...
•
Dec 31, 2019
Phathom Q4 2019 Earnings Report
Phathom reported a net loss, advanced clinical trials, and paused new patient randomization due to COVID-19.
Key Takeaways
Phathom Pharmaceuticals reported a net loss of $98 million for Q4 2019, which included non-cash charges. The company initiated Phase 3 clinical trials for Vonoprazan and paused new patient randomization due to the COVID-19 pandemic. They also completed an initial public offering and appointed Mark Stenhouse to the Board of Directors.
Initiated two pivotal Phase 3 trials (PHALCON-EE and PHALCON-HP) for Vonoprazan.
Temporarily paused new patient randomization in PHALCON-EE and PHALCON-HP trials due to the COVID-19 pandemic.
Completed a $209 million initial public offering.
Mark Stenhouse, General Manager – Screening Business, Exact Sciences, was appointed to the Board of Directors.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...